9 terminated, 5 completed, 2 withdrawn, 1 unknown. 11 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Terminated 6, Completed 3, Unknown 1, Withdrawn 1 |
| Phase 2 | 9 | Terminated 5, Completed 2, Withdrawn 2 |
Follow Celularity Incorporated: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma CYNK-101, Pembrolizumab, Trastuzumab - Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Terminated | Celularity Incorporated | 1 | 2022-04-14 | 2024-12-12 |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type CYNK-001 systemic and Intra cavity administration - Astrocytoma, Grade IV, Glioblastoma | Phase 1 / Phase 2 | Withdrawn | Celularity Incorporated | 2021-09-01 | 2026-06-08 | |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM CYNK001-IV, CYNK001-IT - Astrocytoma, Grade IV, Giant Cell Glioblastoma | Phase 1 | Terminated | Celularity Incorporated | 3 | 2020-10-01 | 2022-08-10 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 CYNK-001 - Coronavirus, Coronavirus Infection | Phase 1 / Phase 2 | Terminated | Celularity Incorporated | 7 | 2020-09-02 | 2026-06-26 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma CYNK-001 - Multiple Myeloma, Neoplasm, Plasma Cell | Phase 1 | Unknown | Celularity Incorporated | 29 | 2020-05-12 | 2023-02-16 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML CYNK-001 - Leukemia, Leukemia, Myeloid | Phase 1 | Terminated | Celularity Incorporated | 27 | 2020-03-12 | 2024-12-12 |
| A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) rhIL-2, PNK-007 - Multiple Myeloma | Phase 1 | Completed | Celularity Incorporated | 15 | 2017-01-05 | 2020-07-22 |
| A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) PNK-007, Cyclophosphamide, Fludarabine - Leukemia, Myeloid, Acute | Phase 1 | Terminated | Celularity Incorporated | 10 | 2016-07-11 | 2020-07-22 |
| A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy PDA-002, Placebo - Diabetic Nephropathies, Peripheral Nervous System Diseases | Phase 2 | Completed | Celularity Incorporated | 26 | 2015-10-27 | 2022-02-02 |
| Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease PDA-002, Placebo - Diabetic Foot, Peripheral Arterial Disease | Phase 2 | Withdrawn | Celularity Incorporated | 2015-06-01 | 2026-04-29 | |
| Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD. PDA-002, Placebo - Peripheral Arterial Disease, Diabetic Foot | Phase 2 | Terminated | Celularity Incorporated | 159 | 2014-10-23 | 2026-06-12 |
| Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers PDA-002 - Peripheral Arterial Disease, Diabetic Foot Ulcer | Phase 1 | Completed | Celularity Incorporated | 15 | 2013-05-23 | 2026-06-04 |
| A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease PDA001, Vehicle Controlled Placebo - Crohns Disease | Phase 1 | Completed | Celularity Incorporated | 14 | 2013-03-01 | 2018-03-01 |
| Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis PDA001 (cenplacel-L) - Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis | Phase 1 | Terminated | Celularity Incorporated | 4 | 2011-09-01 | 2018-03-01 |
| Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke Human Placenta-Derived Cells PDA001- (cenplacel-L), Placebo - Stroke, Acute, Middle Cerebral Artery Stroke | Phase 2 | Terminated | Celularity Incorporated | 44 | 2011-03-01 | 2018-03-01 |
| Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis PDA001, Vehicle Controlled Placebo - Rheumatoid Arthritis | Phase 2 | Terminated | Celularity Incorporated | 26 | 2010-12-01 | 2020-07-22 |
| PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease Human Placenta-Derived Cells PDA001 Intravenous Infusion, Vehicle Control - Crohn's Disease | Phase 2 | Completed | Celularity Incorporated | 50 | 2010-08-01 | 2026-07-07 |
Diabetic Foot (3) · Peripheral Arterial Disease (3) · Crohn Disease (2) · Glioblastoma (2) · Hematologic Diseases (2) · Immune System Diseases (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Multiple Myeloma (2) · Neoplasm, Residual (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Arthritis, Rheumatoid (1) · Blood Protein Disorders (1)
Cyclophosphamide (2) · fludarabine (2) · Mesna (1) · Trastuzumab (1) · aldesleukin (1) · fludarabine phosphate (1) · pembrolizumab (1)
United States (16)
Monica E Luchi, MD (3) · Solveig Ericson, MD (3) · Adrian Kilcoyne, MD (2) · Sharmila Koppisetti, MD (2) · Corey Casper, MD MPH (1) · Sharmila Koppisetti (1) · Sharmila Koppisetti, M.D (1)